February 22, 2013 at 09:28 AM EST
UPDATE: Goldman Sachs Downgrades C.R. Bard to Sell on Clinical Trial Risk
Goldman Sachs downgraded C.R. Bard (NYSE: BCR ) from Neutral to Sell and lowered the price target from $99.00 to $95.00. Goldman Sachs noted, "With BCR's FY1 P/E multiple having expanded 11.6% vs. an 8% cut to earnings estimates, we think the market is giving Bard too much credit for
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here